ICI-164384

ICI-164384

ICI-164384 is a nonsteroidal antiestrogen that was developed for the treatment of breast cancer. It is a member of the class of compounds known as selective estrogen receptor modulators (SERMs). Unlike other SERMs, ICI-164384 acts as a pure antiestrogen, meaning it does not exhibit any estrogen-like effects in tissues.

Mechanism of Action

ICI-164384 works by binding to the estrogen receptors (ERs) in breast tissue, thereby blocking the effects of estrogen. This inhibition prevents the growth and proliferation of estrogen receptor-positive breast cancer cells. The compound has a high affinity for the ER, making it a potent antiestrogen.

Clinical Use

Although ICI-164384 showed promise in preclinical studies, it was never marketed for clinical use. However, its development has contributed to the understanding of estrogen receptor modulation and has paved the way for the development of other antiestrogens, such as fulvestrant.

Research

ICI-164384 has been extensively studied in preclinical models to understand its effects on estrogen receptor signaling. Research has shown that it can effectively inhibit the growth of breast cancer cells in vitro and in vivo. Studies have also explored its potential use in combination with other anticancer drugs to enhance therapeutic efficacy.

Related Compounds

ICI-164384 is structurally related to other antiestrogens, including tamoxifen and raloxifene. However, unlike these compounds, ICI-164384 does not have any partial agonist activity, making it a pure antiestrogen.

See Also

• Selective estrogen receptor modulator
• Estrogen receptor
• Breast cancer
• Fulvestrant
• Tamoxifen
• Raloxifene